Table 4. Characteristics of randomized controlled trials comparing the LNG-IUS and oral progestin for treatment of EH.
| Author | Population | Intervention | Comparison | Diagnostic method | Follow-up evaluation | Treatment outcome (regression rate) |
|---|---|---|---|---|---|---|
| Ismail et al., 2013 [19] | 90 women with non-atypical SEH | LNG-IUS (n=30) for 3 mo | MPA 10 mg/day for 10 day/cycle (n=30), or NET 15 mg/day for 10 day/cycle (n=30) | D&C | Aspiration biopsy | LNG-IUS group: 66.67%; MPA group: 36.66%; NET group: 40% |
| Abu Hashim et al., 2013 [11] | 120 women with non-atypical EH | LNG-IUS (n=59) for 3-6 mo | NET (n=61) 15 mg/day for 3 wk/cycle | Hysteroscopy with D&C | Aspiration biopsy | LNG-IUS group vs. NET group at the 3rd, 6th and 12th mo: 67.8% vs. 47.5%, RR, 1.42; 79.7% vs. 60.7%, RR, 1.31; and 88.1% vs. 55.7%, RR, 1.58, respectively |
| Dolapcioglu et al., 2013 [20] | 104 women with non-atypical EH | LNG-IUS (3, 6-month treatment subgroups; n=26 for each one) | MPA 10 mg/day for 10 d/cycle (3, 6-month treatment subgroups; n=26 for each one) | D&C; Aspiration biopsy | D&C; Aspiration biopsy | LNG-IUS group vs. MPA group: at the 3rd, 6th mo: 84% vs. 50%, 100% vs. 64%, respectively |
| Behnamfar et al., 2014 [21] | 60 women with non-atypical EH | LNG-IUS (n=30) for 3 mo | MPA (n=30), 10 mg/day for 12 day/cycle | - | Aspiration biopsy | LNG-IUS group: 89.3%; MPA group: 70.4% |
| El Behery et al., 2015 [22] | 100 women with non-atypical EH | LNG-IUS (n=50) for 6 mo | Dydrogesterone (n=50) 20 mg for 16 day/cycle | D&C | D&C | LNG-IUS group: 96%; Dydrogesterone group: 80% |
| Abdelaziz and Abosrie, 2013 [23] | 84 women with non-atypical SEH | LNG-IUS (n=42) for 3 mo | NET (n=42); 15 mg/day continuously | Hysteroscopy | Aspiration biopsy | LNG-IUS group: 73.8%; NET group: 57.1% |
| Ørbo et al., 2014 [24] | 153 women with non-atypical EH | LNG-IUS (n=53) for 6 mo | Cyclic MPA 10 mg/day for 10 day/cycle (n=52), or continuous MPA 10 mg daily (n=48) | Aspiration biopsy | Aspiration biopsy | LNG-IUS group: 100%; continuous MPA group: 96%; cyclic MPA group: 69% |
EH, endometrial hyperplasia; D&C, dilatation and curettage; LNG-IUS, levonorgestrel-releasing intrauterine system; MPA, medroxyprogesterone acetate; NET, norethisterone acetate; RR, relative risk; SEH, simple endometrial hyperplasia.